Page 71 - Read Online

Milluzzo et al. Metab Target Organ Damage 2024;4:5 https://dx.doi.org/10.20517/mtod.2023.43 Page 13 of 14
20. Gianni L, Panzini I, Li S, et al; International Breast Cancer Study Group (IBCSG). Ocular toxicity during adjuvant chemoendocrine
therapy for early breast cancer: results from International Breast Cancer Study Group trials. Cancer 2006;106:505-13. DOI
21. Lamba N, Anderson-Nelson S. Medication induced retinal side effects. Dis Mon 2014;60:263-7. DOI PubMed
22. Moussa K, Kim J, Miller JB. Retinal exudates and hemorrhages in a survivor of breast cancer. JAMA Ophthalmol 2019;137:218-9.
DOI
23. Bommireddy T, Carrim ZI. To stop or not? Tamoxifen therapy for secondary prevention of breast cancer in a patient with ocular
toxicity BMJ Case Rep 2016;2016:bcr2015213431. DOI PubMed PMC
24. Bradley MC, Zhou Y, Freedman AN, et al. Risk of diabetes complications among those with diabetes receiving androgen deprivation
therapy for localized prostate cancer. Cancer Causes Control 2018;29:785-91. DOI PubMed PMC
25. Derweesh IH, Diblasio CJ, Kincade MC, et al. Risk of new-onset diabetes mellitus and worsening glycaemic variables for established
diabetes in men undergoing androgen-deprivation therapy for prostate cancer. BJU Int 2007;100:1060-5. DOI
26. Keating NL, Liu PH, O'Malley AJ, Freedland SJ, Smith MR. Androgen-deprivation therapy and diabetes control among diabetic men
with prostate cancer. Eur Urol 2014;65:816-24. DOI PubMed PMC
27. Hershey DS, Bryant AL, Olausson J, Davis ED, Brady VJ, Hammer M. Hyperglycemic-inducing neoadjuvant agents used in treatment
of solid tumors: a review of the literature. Oncol Nurs Forum 2014;41:E343-54. DOI PubMed
28. Matsuyama K, Ando A, Wada M, Ogata N, Nishimura T. Case of ischemic retinopathy induced by chemotherapy with paclitaxel and
carboplatin. Acta Ophthalmol 2008;86:0-0. DOI
29. Elhusseiny AM, Smiddy WE. Carboplatin- and/or paclitaxel-induced ischemic retinopathy. Can J Ophthalmol 2020;55:e95-8. DOI
PubMed
30. Bassi E, Loizzi V, Furino C, et al. Cystoid macular edema secondary to paclitaxel therapy for ovarian cancer: a case report. Mol Clin
Oncol 2017;7:285-7. DOI PubMed PMC
31. Chelala E, Arej N, Antoun J, et al. Central macular thickness monitoring after a taxane-based therapy in visually asymptomatic
patients. Chemotherapy 2017;62:199-204. DOI
32. Hilliard LM, Berkow RL, Watterson J, Ballard EA, Balzer GK, Moertel CL. Retinal toxicity associated with cisplatin and etoposide in
pediatric patients. Med Pediatr Oncol 1997;28:310-3. DOI PubMed
33. Kwan AS, Sahu A, Palexes G. Retinal ischemia with neovascularization in cisplatin related retinal toxicity. Am J Ophthalmol
2006;141:196-7. DOI PubMed
34. Tran THC, Desauw C, Rose C. Gemcitabine-induced retinopathy in a diabetic patient. Acta Ophthalmol 2009;87:114-5. DOI
35. Higashide T, Murotani E, Sugiyama K. Cystoid macular edema associated with oral antineoplastic agent s-1 in a patient with diabetic
retinopathy. Case Rep Ophthalmol 2012;3:91-5. DOI PubMed PMC
36. Méndez-Martínez S, Calvo P, Ruiz-Moreno O, et al. Ocular adverse events associated with mek inhibitors. Retina 2019;39:1435-50.
DOI
37. AlAli A, Bushehri A, Park JC, Krema H, Lam WC. Pimasertib and serous retinal detachments. Retin Cases Brief Rep 2016;10:191-6.
DOI PubMed PMC
38. Avery RA, Trimboli-Heidler C, Kilburn LB. Separation of outer retinal layers secondary to selumetinib. J AAPOS 2016;20:268-71.
DOI PubMed PMC
39. van Dijk EHC, Kruit WHJ, Jager MJ, Luyten GPM, Vingerling JR, Boon CJF. Pimasertib-associated ophthalmological adverse
events. Acta Ophthalmol 2018;96:712-8. DOI PubMed
40. van Dijk EH, van Herpen CM, Marinkovic M, et al. Serous retinopathy associated with mitogen-activated protein kinase kinase
inhibition (binimetinib) for metastatic cutaneous and uveal melanoma. Ophthalmology 2015;122:1907-16. DOI
41. Watanabe K, Otsu S, Hirashima Y, et al. A phase I study of binimetinib (MEK162) in Japanese patients with advanced solid tumors.
Cancer Chemother Pharmacol 2016;77:1157-64. DOI
42. Rueda-Rueda T, Sánchez-Vicente JL, Moruno-Rodríguez A, Molina-Socola FE, Martínez-Borrego AC, López-Herrero F. Uveitis and
serous retinal detachment secondary to systemic dabrafenib and trametinib. Arch Soc Esp Oftalmol 2018;93:458-62. DOI PubMed
43. Gulati AP, Saif MW. Retinal neovascularization and hemorrhage associated with the use of imatinib (Gleevec(®)) in a patient being
treated for gastrointestinal stromal tumor (GIST). Anticancer Res 2012;32:1375-7. PubMed
44. Breccia M, Gentilini F, Cannella L, et al. Ocular side effects in chronic myeloid leukemia patients treated with imatinib. Leuk Res
2008;32:1022-5. DOI
45. Kitzmann AS, Baratz KH, Mohney BG, et al. Histologic studies of the intraocular toxicity of imatinib mesylate in rabbits. Eye
2008;22:712-4. DOI
46. Fraunfelder FT, Fraunfelder FW. Oral anti-vascular endothelial growth factor drugs and ocular adverse events. J Ocul Pharmacol Ther
2018;34:432-5. DOI PubMed
47. Javle M, Roychowdhury S, Kelley RK, et al. Infigratinib (BGJ398) in previously treated patients with advanced or metastatic
cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study.
Lancet Gastroenterol Hepatol 2021;6:803-15. DOI PubMed
48. Lam WS, Creaney J, Chen FK, et al. A phase II trial of single oral FGF inhibitor, AZD4547, as second or third line therapy in
malignant pleural mesothelioma. Lung Cancer 2020;140:87-92. DOI PubMed
49. Akturk HK, Kahramangil D, Sarwal A, Hoffecker L, Murad MH, Michels AW. Immune checkpoint inhibitor-induced Type 1 diabetes:
a systematic review and meta-analysis. Diabet Med 2019;36:1075-81. DOI PubMed PMC
50. Dalvin LA, Shields CL, Orloff M, Sato T, Shields JA. Checkpoint inhibitor immune therapy: systemic indications and ophthalmic side